Fluticasone

WASHINGTON —Tertiary care center providers generally reported similar asthma inhaler practices despite being from different disciplines, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

An exhalation delivery system that uses fluticasone reduced symptoms and improved quality of life for patients with chronic rhinosinusitis, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Improvements observed with triple therapy with umeclidinium, fluticasone furoate and vilanterol, and use of a higher fluticasone furoate dose, were consistent regardless of age at asthma onset, according to new data from the CAPTAIN study.

Nicox has initiated a phase 2b clinical trial to evaluate NCX 4251 vs. placebo in patients with acute exacerbations of blepharitis, according to a press release.

APT-1011, a novel fluticasone orally disintegrating tablet, effectively induced histologic response, improved symptoms and decreased endoscopic severity, according to a presentation at the American College of Gastroenterology Virtual Annual Meeting.

The FDA has approved Trelegy Ellipta, once-daily, single-inhaler triple therapy, for the new indication of treatment of asthma in adults, according to a company announcement.

The tablet formulation of fluticasone was safe and well tolerated in adolescents and adults with eosinophilic esophagitis.